Oculis (OCS) Competitors $18.95 -0.21 (-1.07%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. MLTX, MTSR, VKTX, KYMR, MOR, CRNX, ALVO, IMVT, CPRX, and HCMShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors MoonLake Immunotherapeutics Metsera Viking Therapeutics Kymera Therapeutics MorphoSys Crinetics Pharmaceuticals Alvotech Immunovant Catalyst Pharmaceuticals HUTCHMED Oculis (NASDAQ:OCS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk. Do analysts rate OCS or MLTX? Oculis currently has a consensus target price of $35.33, suggesting a potential upside of 86.41%. MoonLake Immunotherapeutics has a consensus target price of $74.50, suggesting a potential upside of 60.68%. Given Oculis' higher possible upside, analysts clearly believe Oculis is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor OCS or MLTX? In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 2 mentions for MoonLake Immunotherapeutics and 1 mentions for Oculis. MoonLake Immunotherapeutics' average media sentiment score of 0.82 beat Oculis' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is OCS or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. MoonLake Immunotherapeutics' return on equity of -30.81% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-13,788.70% -92.95% -70.03% MoonLake Immunotherapeutics N/A -30.81%-28.40% Do insiders and institutionals have more ownership in OCS or MLTX? 22.3% of Oculis shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, OCS or MLTX? Oculis has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Which has higher earnings and valuation, OCS or MLTX? Oculis has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$780K1,060.99-$97.43M-$2.64-7.18MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.30-20.16 SummaryMoonLake Immunotherapeutics beats Oculis on 10 of the 14 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$829.58M$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-7.1821.5627.6120.24Price / Sales1,060.99278.93417.30118.22Price / CashN/A42.7336.8958.10Price / Book9.927.518.035.67Net Income-$97.43M-$55.14M$3.18B$249.21M7 Day Performance-2.04%4.61%2.93%3.28%1 Month Performance-3.09%4.72%3.75%5.55%1 Year Performance62.56%5.92%35.20%21.09% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis1.7484 of 5 stars$18.96-1.1%$35.33+86.4%+61.7%$829.58M$780K-7.182News CoverageMLTXMoonLake Immunotherapeutics2.1639 of 5 stars$47.20-0.7%$74.50+57.8%+9.9%$3.04BN/A-20.522News CoverageMTSRMetseraN/A$28.45-0.5%$55.00+93.3%N/A$3.00BN/A0.0081Gap DownVKTXViking Therapeutics4.3603 of 5 stars$26.50-0.1%$87.15+228.9%-44.2%$2.98BN/A-23.0420Trending NewsInsider TradeKYMRKymera Therapeutics3.1711 of 5 stars$43.64-1.1%$59.61+36.6%+48.6%$2.87B$47.07M-14.08170Positive NewsAnalyst ForecastInsider TradeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730News CoverageCRNXCrinetics Pharmaceuticals3.3052 of 5 stars$28.76-4.0%$74.56+159.2%-32.4%$2.81B$1.04M-7.53210ALVOAlvotech3.5282 of 5 stars$9.12-0.2%$18.00+97.4%-24.4%$2.76B$491.98M24.651,032IMVTImmunovant1.4086 of 5 stars$16.00-0.6%$38.33+139.6%-35.9%$2.75BN/A-5.84120CPRXCatalyst Pharmaceuticals4.9181 of 5 stars$21.70-0.4%$32.83+51.3%+41.3%$2.66B$491.73M13.8280HCMHUTCHMED1.3545 of 5 stars$15.05-0.3%$19.00+26.2%-9.3%$2.63B$630.20M0.001,811Positive News Related Companies and Tools Related Companies MLTX Competitors MTSR Competitors VKTX Competitors KYMR Competitors MOR Competitors CRNX Competitors ALVO Competitors IMVT Competitors CPRX Competitors HCM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
